Skip to main content
Review time for Samsung's cancer drug extended by FDA
11/9/2018

The FDA required an extension of three months to review Samsung Bioepis' biologics license application for cancer drug SB3, a biosimilar of Roche Holding unit Genentech's Herceptin, or trastuzumab. The agency is expected to give its decision in January.

Full Story: